ALNY vs MRNA Stock Comparison

Alnylam Pharmaceuticals and Moderna Prices as of Nov 13, 2026 Peers: Industry group
MRNA Moderna, Inc.
$223.37 -1.3% 1M +794.9% 1Y
Market cap
$86.19B
P/E
–
Revenue (TTM)
$2.53B
Div. yield
–
Biotechnology Healthcare
3 wins

Head to Head

8 decided of 12

Alnylam Pharmaceuticals leads on 5 of the 12 questions below (Alnylam Pharmaceuticals 5, Moderna 3). Which ones matter depends on what you are buying for; a cheap multiple and slow growth often come together.

QuestionALNYMRNALeader
Larger companyMarket capitalisation $21.44B $86.19B MRNA
Cheaper on earningsLower P/E, profitable companies only 8.1x -30.9x –
Cheaper on forward earningsLower price / next fiscal year consensus EPS 8.6x — –
Faster revenue growthRevenue growth, trailing twelve months +60.8% +13.1% ALNY
More profitableNet margin, trailing twelve months 52.8% -110.5% ALNY
Better return on capitalReturn on invested capital — -39.6% –
Less leveragedLower net debt / EBITDA -3.1x 1.7x ALNY
Higher dividend yieldTrailing dividend yield 0.00% 0.00% –
Better 1-year returnPrice return, last 12 months -63.6% +794.9% MRNA
Better 5-year returnAnnualised price return, 5 years -0.7%/yr -0.7%/yr MRNA
Less volatileAnnualised volatility, 1 year 59.1% 130.6% ALNY
Higher overall scoreMean of the five percentile scores vs peers 81/100 60/100 ALNY

Percentile Scorecard

ALNYMRNA

Each axis is the mean percentile of its metrics against the company's industry group. 100 is the best in the group, 50 the middle.

Scores by Axis

AxisALNYMRNA
Valuation 91 #61 of 660 69 #208 of 660
Growth 99 #10 of 619 45 #344 of 619
Profitability 91 #55 of 595 60 #239 of 595
Financial Health 61 #269 of 683 52 #330 of 683
Shareholder Returns 66 #156 of 459 76 #112 of 459
Overall 81 60
  • ALNY ranked among 695 companies in Pharmaceuticals and Biotechnology
  • MRNA ranked among 695 companies in Pharmaceuticals and Biotechnology

Price Performance

Price return, split-adjusted, before dividends. Click a name to hide or show it.

Returns

PeriodALNYMRNASPY
1 month -26.5%-1.3% -2.0%
3 months -27.8%+252.8% -2.8%
6 months -42.5%+355.5% +2.0%
Year to date -58.5%+657.4% +10.6%
1 year -63.6%+794.9% +12.2%
3 years -2.9%+201.4% +68.1%
3 years, per year -1.0%+44.5% +18.9%
5 years -3.4%-3.4% +61.4%
5 years, per year -0.7%-0.7% +10.1%
10 years +254.6%— +248.5%
10 years, per year +13.5%— +13.3%

Risk

MeasureALNYMRNASPY
Volatility, 1Y 59.1%130.6% 13.6%
Downside volatility, 1Y 74.1%79.2% 13.9%
Beta vs S&P 500, 1Y 0.502.26 1.00
Return / volatility, 1Y -1.086.09 0.90
Max drawdown, 5Y -69.1%-93.9% -25.4%
From 52-week high -65.1%-16.9% -3.2%
52-week high $473.29$268.86 $779.14
52-week low $151.64$22.36 $631.97

Valuation History

Weekly multiples on trailing twelve-month fundamentals. Negative or extreme readings (a loss year, a collapsed denominator) are left out so the chart stays readable.

MultipleALNYMRNA
P/E now vs peer median 8.3xmedian 17.0x -32.1xmedian 17.0x
P/S now vs peer median 4.4xmedian 8.4x 35.7xmedian 8.4x
EV/EBITDA now vs peer median 18.3xmedian 14.6x -32.0xmedian 14.6x
P/FCF now vs peer median 27.4xmedian 19.0x -45.8xmedian 19.0x
P/B now vs peer median 6.1xmedian 2.0x 13.2xmedian 2.0x
PEG now vs peer median 0.09median 0.43 -3.01median 0.43

Financial History

Reported figures by fiscal period, placed on the calendar year (or quarter) each period ended in, so companies with different fiscal years line up.

Trailing twelve monthsALNYMRNA
Revenue $5.01B $2.53B
Gross profit $3.88B $707.00M
Operating income $977.59M -$2.93B
Net income $2.65B -$2.79B
Free cash flow $806.31M -$1.97B
R&D $1.56B $2.66B
EPS (diluted) $19.19 $-6.49
Cash & equivalents $1.75B $1.20B
Total debt $361.53M $591.00M
Shares (diluted) 138.04M 430.00M
Enterprise value $8.63B $64.88B

All Metrics

58 metrics · best in bold

Bold marks the best reading: the lowest positive value for multiples, leverage and payout, the highest for everything else. The bar under each value is its percentile against that company's own peers. Hover a value for its rank and the peer median.

Valuation

12 metrics
MetricALNYMRNA
P/E 8.3x -32.1x
P/FCF 27.4x -45.8x
P/Operating cash flow 23.1x -50.6x
P/S 4.4x 35.7x
P/B 6.1x 13.2x
P/Tangible book 6.1x 13.2x
EV/EBITDA 18.3x -32.0x
EV/EBIT 19.3x -29.2x
EV/Revenue 3.8x 33.9x
EV/FCF 23.4x -43.5x
EV/Operating cash flow 19.7x -48.0x
PEG (3Y EPS CAGR) 0.09 -3.01

Growth

14 metrics
MetricALNYMRNA
Revenue growth (1Y) 60.8% 13.1%
Revenue CAGR (3Y) 42.7% -34.8%
Gross profit growth (1Y) 49.6% -34.4%
Gross profit CAGR (3Y) 37.8% -41.0%
Operating income growth (1Y) 269.3% 15.4%
Operating income CAGR (3Y) 68.2% -3.2%
Net income growth (1Y) 2,137% 10.5%
Net income CAGR (3Y) 93.1% 7.0%
EPS growth (1Y) 2,126% 18.8%
EPS CAGR (3Y) 90.8% 10.7%
Operating cash flow growth (1Y) 351.6% 9.8%
Operating cash flow CAGR (3Y) 685.4% 4.9%
Free cash flow growth (1Y) 382.3% 25.7%
Free cash flow CAGR (3Y) 141.7% 9.5%

Profitability

14 metrics
MetricALNYMRNA
Gross margin 77.4% 28.0%
EBITDA margin 20.6% -105.9%
Operating margin 19.5% -116.0%
Pretax margin 15.6% -108.1%
Net margin 52.8% -110.5%
FCF margin 16.1% -78.0%
Operating cash flow margin 19.1% -70.7%
Return on equity 106.4% -41.0%
Return on assets 38.9% -22.8%
Return on invested capital – -39.6%
Return on capital employed 20.7% -28.8%
Asset turnover 0.7x 0.2x
Cash conversion (OCF / net income) 0.4x 0.6x
Stock comp / revenue 6.1% 18.4%

Financial Health

11 metrics
MetricALNYMRNA
Debt / assets 4.5% 4.4%
Debt / equity 0.1x 0.1x
Net debt / EBITDA -3.1x 1.7x
Debt / FCF 0.4x -0.3x
Liabilities / assets 54.9% 49.2%
Equity / assets 45.1% 50.8%
Interest coverage 3.2x –
Current ratio 2.5x 3.6x
Quick ratio 2.3x 3.2x
Cash ratio 1.7x 2.5x
Altman Z-score 3.78 8.66

Shareholder Returns

7 metrics
MetricALNYMRNA
Dividend yield – –
Net buyback yield -0.5% -0.2%
Shareholder yield -0.5% -0.2%
Payout ratio (earnings) – –
Payout ratio (FCF) – –
Dividend growth (1Y) – –
Dividend CAGR (3Y) – –

Analyst Estimates

Solid lines are reported fiscal-year results; dashed lines are the consensus for the years ahead. Hover a year for the analysts' high and low, and how each result compared with its estimate.

ConsensusALNYMRNA
Forward P/E 8.6xFY2026 –
EPS, next fiscal year $19.15FY2026 $-7.17FY2026
EPS growth, next FY +721.9%FY2026 –
EPS growth, the year after -56.0% –
Revenue, next fiscal year $5.65BFY2026 $2.22BFY2026
Revenue growth, next FY +52.2%FY2026 +14.6%FY2026
Revenue growth, the year after +23.3% +25.8%

Institutional Ownership

13F filings, quarter ended Jun 30, 2026
HoldersALNYMRNA
Held by institutions 99.7% 80.2%
Institutions holding 788 787
Change in shares held, QoQ +3.8% +3.4%
Institutions buying 412 404
Institutions selling 279 239
Buyers to sellers 1.48 1.69

Return Correlation

Daily returns, last 12 months

1.00 means two stocks move in lockstep, 0 that they move independently. Pairs below about 0.5 diversify each other.

ALNYMRNA
ALNY 1.00 0.18
MRNA 0.18 1.00

Add a Peer

Largest companies in the same industry

Related Comparisons

Frequently Asked Questions

Which is bigger, ALNY and MRNA?

Moderna (MRNA) is the largest by market capitalisation: Alnylam Pharmaceuticals (ALNY) $21.44B, Moderna (MRNA) $86.19B.

Which company is growing faster?

Alnylam Pharmaceuticals (ALNY) grew revenue fastest over the trailing twelve months: Alnylam Pharmaceuticals (ALNY) +60.8%, Moderna (MRNA) +13.1%.

Which company is more profitable?

Alnylam Pharmaceuticals (ALNY) has the highest net margin (Alnylam Pharmaceuticals (ALNY) 52.8%, Moderna (MRNA) -110.5%).

Which stock has performed better?

Over the past year Moderna (MRNA) returned the most: Alnylam Pharmaceuticals (ALNY) -63.6%, Moderna (MRNA) +794.9%. Over five years, Moderna (MRNA) compounded fastest (Alnylam Pharmaceuticals (ALNY) -0.7%/yr, Moderna (MRNA) -0.7%/yr). Returns are price only, before dividends.

Which stock is riskier?

By one-year price volatility, Alnylam Pharmaceuticals (ALNY) has been the steadiest (Alnylam Pharmaceuticals (ALNY) 59.1%, Moderna (MRNA) 130.6%). Volatility measures how widely the price swings, not the risk of the business.

Do ALNY and MRNA move together?

Their daily returns over the past year have a correlation of 0.18, a weak relationship. Holding both diversifies more than two closely linked stocks would.

Which is the better stock, ALNY and MRNA?

There is no single answer; it depends on what you are buying for. On the 12 head-to-head measures on this page, Alnylam Pharmaceuticals (ALNY) leads on 5. Business Quant does not give investment advice; use the comparison as a starting point for your own research.

Data from SEC filings, exchange prices and consensus estimates, via Business Quant. Percentile scores compare each company with its own peer group, so two companies' scores are each relative to different peers unless you rank against the whole market. Price returns exclude dividends. Nothing on this page is investment advice.